NI201300081A - Uso de 3 - ( 5 - amino - 2 - metil - 4 - oxoquinazolin - 3(4h) - il) piperidin - 2 - 6 -diona en el tratamiento de enfermedades relacionadas con el sistema inmunitario e inflamatorias. - Google Patents

Uso de 3 - ( 5 - amino - 2 - metil - 4 - oxoquinazolin - 3(4h) - il) piperidin - 2 - 6 -diona en el tratamiento de enfermedades relacionadas con el sistema inmunitario e inflamatorias.

Info

Publication number
NI201300081A
NI201300081A NI201300081A NI201300081A NI201300081A NI 201300081 A NI201300081 A NI 201300081A NI 201300081 A NI201300081 A NI 201300081A NI 201300081 A NI201300081 A NI 201300081A NI 201300081 A NI201300081 A NI 201300081A
Authority
NI
Nicaragua
Prior art keywords
inflammatory
related diseases
immune
oxoquinazoline
diona
Prior art date
Application number
NI201300081A
Other languages
English (en)
Spanish (es)
Inventor
Gandhi Anita
H Schafer Peter
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of NI201300081A publication Critical patent/NI201300081A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medical Informatics (AREA)
  • Electromagnetism (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
NI201300081A 2011-03-11 2013-09-09 Uso de 3 - ( 5 - amino - 2 - metil - 4 - oxoquinazolin - 3(4h) - il) piperidin - 2 - 6 -diona en el tratamiento de enfermedades relacionadas con el sistema inmunitario e inflamatorias. NI201300081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161451995P 2011-03-11 2011-03-11
US201161480272P 2011-04-28 2011-04-28

Publications (1)

Publication Number Publication Date
NI201300081A true NI201300081A (es) 2014-02-25

Family

ID=45876915

Family Applications (2)

Application Number Title Priority Date Filing Date
NI201300082A NI201300082A (es) 2011-03-11 2013-09-09 Métodos de tratamiento del cáncer utilizando 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona.
NI201300081A NI201300081A (es) 2011-03-11 2013-09-09 Uso de 3 - ( 5 - amino - 2 - metil - 4 - oxoquinazolin - 3(4h) - il) piperidin - 2 - 6 -diona en el tratamiento de enfermedades relacionadas con el sistema inmunitario e inflamatorias.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NI201300082A NI201300082A (es) 2011-03-11 2013-09-09 Métodos de tratamiento del cáncer utilizando 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona.

Country Status (29)

Country Link
US (6) US20140148473A1 (OSRAM)
EP (3) EP3025715A1 (OSRAM)
JP (5) JP6118273B2 (OSRAM)
KR (2) KR20140025374A (OSRAM)
CN (3) CN107375293A (OSRAM)
AR (1) AR085651A1 (OSRAM)
AU (4) AU2012229316B2 (OSRAM)
BR (2) BR112013023277A2 (OSRAM)
CA (2) CA2829593A1 (OSRAM)
CY (1) CY1117430T1 (OSRAM)
DK (1) DK2683384T3 (OSRAM)
EA (2) EA201391319A1 (OSRAM)
ES (2) ES2562332T3 (OSRAM)
HR (1) HRP20160056T1 (OSRAM)
HU (1) HUE027481T2 (OSRAM)
IL (2) IL227990B (OSRAM)
MX (2) MX2013010217A (OSRAM)
NI (2) NI201300082A (OSRAM)
PH (2) PH12013501820A1 (OSRAM)
PL (1) PL2683384T3 (OSRAM)
PT (1) PT2683384E (OSRAM)
RS (1) RS54553B1 (OSRAM)
RU (3) RU2013145556A (OSRAM)
SG (2) SG193320A1 (OSRAM)
SI (1) SI2683384T1 (OSRAM)
SM (1) SMT201600034B (OSRAM)
TW (2) TW201700100A (OSRAM)
WO (2) WO2012125475A1 (OSRAM)
ZA (2) ZA201306148B (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107445940A (zh) 2006-09-26 2017-12-08 细胞基因公司 作为抗肿瘤剂的5‑取代的喹唑酮衍生物
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
UA113512C2 (xx) 2011-03-11 2017-02-10 Тверда форма 3-(5-аміно-2-метил-4-оксо-4h-хіназолін-3-іл)піперидин-2,6-діону і її фармацевтична композиція та застосування
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US9365640B2 (en) * 2011-04-29 2016-06-14 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
SI2882442T1 (sl) * 2012-08-09 2021-11-30 Celgene Corporation Metode zdravljenja raka z uporabo 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin- 2,6-diona
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
WO2014039421A1 (en) 2012-09-04 2014-03-13 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
US9694015B2 (en) * 2012-09-10 2017-07-04 Celgene Corporation Methods for the treatment of locally advanced breast cancer
US9540340B2 (en) * 2013-01-14 2017-01-10 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
WO2014152833A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014172436A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
NZ631082A (en) * 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
JP6490055B2 (ja) * 2013-05-01 2019-03-27 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの合成
EP2991651A1 (en) 2013-05-03 2016-03-09 Celgene Corporation Methods for treating cancer using combination therapy
US20160282354A1 (en) 2013-11-08 2016-09-29 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
AU2014360328B2 (en) * 2013-12-06 2021-04-01 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
WO2015108889A1 (en) * 2014-01-15 2015-07-23 Celgene Corporation Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
EP3827836A1 (en) 2014-06-27 2021-06-02 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
WO2016007854A1 (en) * 2014-07-11 2016-01-14 Celgene Corporation Combination therapy for cancer
JP7120763B2 (ja) 2014-08-22 2022-08-17 セルジーン コーポレイション 免疫調節化合物を抗体と併用する多発性骨髄腫の治療方法
MX391191B (es) 2014-11-17 2025-03-21 Context Biopharma Inc Composiciones de liberación extendida de onapristona y métodos.
TW201642857A (zh) * 2015-04-06 2016-12-16 西建公司 以組合療法治療肝細胞癌
WO2017004532A1 (en) * 2015-07-02 2017-01-05 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US10064863B2 (en) * 2015-08-27 2018-09-04 Celgene Corporation Formulations of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
EP3347717A4 (en) * 2015-09-11 2019-06-05 The Brigham and Women's Hospital, Inc. PROCESS FOR CHARACTERIZING THE RESISTANCE TO CEREBLON MODULATORS
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
MX2018006779A (es) * 2015-12-02 2018-08-01 Celgene Corp Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona.
MX2018007154A (es) 2015-12-15 2019-01-10 Context Biopharma Inc Composiciones de onapristona amorfa y metodos para hacer las mismas.
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
JP6930748B2 (ja) 2016-01-14 2021-09-01 カンプ・バイオファーマスーティカルズ、リミテッドＫａｎｇｐｕ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｌｔｄ キナゾリン誘導体、そのための調製方法、医薬組成物、および適用
JP7264642B2 (ja) * 2016-03-16 2023-04-25 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド エフェクターｔ細胞機能を増進するための、セレブロンを標的とする小分子
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
US20180258064A1 (en) * 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
IL271491B2 (en) * 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
WO2019077968A1 (en) 2017-10-18 2019-04-25 Canon Kabushiki Kaisha PACKAGING CONTAINER AND PACKAGE
US10584133B2 (en) * 2018-03-30 2020-03-10 Biotheryx, Inc. Thienopyrimidinone compounds
PE20210184A1 (es) 2018-07-11 2021-02-02 H Lee Moffitt Cancer Ct & Res Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon
CN112654619B (zh) * 2018-09-07 2022-08-30 南京明德新药研发有限公司 三环并呋喃取代哌啶二酮类化合物
KR20210069642A (ko) 2018-10-01 2021-06-11 셀진 코포레이션 암 치료를 위한 병용 요법
JP7300687B2 (ja) 2019-03-22 2023-06-30 ユニヴァーシティー オブ ウルサン ファウンデイション フォー インダストリー コーオペレイション 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体
EP4126847A1 (en) * 2020-03-30 2023-02-08 ENYO Pharma Quinazolinone derivatives and uses thereof for treating a cancer
TW202416995A (zh) * 2022-08-16 2024-05-01 比利時商艾托斯比利時公司 用於治療與至少一種抗體分泌細胞標記物之表現相關的疾病的腺苷受體拮抗劑及其組合物
CN118844365A (zh) * 2024-06-26 2024-10-29 华南理工大学 一种化疗诱发的血液毒性斑马鱼模型及其应用
CN119161336B (zh) * 2024-07-24 2025-09-05 四川大学 一种作为Blimp1抑制剂的小分子化合物及其用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries, Ltd. Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU1325102A (en) 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
CA2428092A1 (en) * 2000-12-06 2002-06-13 Applied Research Systems Ars Holding N.V. Use of sarp-1 for the treatment and/or prevention of scleroderma
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
EP1824796A4 (en) 2004-11-16 2010-02-17 Avidia Res Inst PROTEIN SKELETONS AND USES THEREOF
US20080051379A1 (en) 2004-12-01 2008-02-28 Trustees Of Boston University Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
CN107445940A (zh) * 2006-09-26 2017-12-08 细胞基因公司 作为抗肿瘤剂的5‑取代的喹唑酮衍生物
GB0709092D0 (en) * 2007-05-11 2007-06-20 Borrebaeck Carl Diagnosis and method of disease
BRPI0817525A2 (pt) * 2007-09-26 2014-11-18 Celgene Corp Composto, composição farmacêutica, e, metódo de tratamento, controle ou prevenção de uma doença ou distúrbio.
EP2232267A1 (en) * 2007-12-07 2010-09-29 Celgene Corporation Biomarkers for monitoring the treatment by quinazolinone compounds
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
US9365640B2 (en) * 2011-04-29 2016-06-14 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

Also Published As

Publication number Publication date
KR20140019364A (ko) 2014-02-14
NI201300082A (es) 2014-02-25
US20160136167A1 (en) 2016-05-19
CN103561743A (zh) 2014-02-05
AU2017210633A1 (en) 2017-08-24
RU2017120977A (ru) 2018-11-15
US8906932B2 (en) 2014-12-09
JP6348192B2 (ja) 2018-06-27
EP2683383B1 (en) 2017-11-29
US20150126538A1 (en) 2015-05-07
KR20140025374A (ko) 2014-03-04
ES2659205T3 (es) 2018-03-14
ZA201306148B (en) 2014-10-29
EA201691939A1 (ru) 2017-05-31
SG193320A1 (en) 2013-10-30
DK2683384T3 (da) 2016-02-08
JP2017101052A (ja) 2017-06-08
RU2013145524A (ru) 2015-04-20
BR112013023277A2 (pt) 2017-06-27
IL227990B (en) 2018-02-28
PT2683384E (pt) 2016-03-11
NZ614493A (en) 2016-01-29
JP2017081959A (ja) 2017-05-18
TW201700100A (zh) 2017-01-01
EP2683384A1 (en) 2014-01-15
EP2683383A1 (en) 2014-01-15
ZA201306305B (en) 2014-10-29
RS54553B1 (sr) 2016-06-30
IL227990A0 (en) 2013-09-30
MX2013010153A (es) 2013-09-26
CA2829592A1 (en) 2012-09-20
CA2829593A1 (en) 2012-09-20
AU2017204402A1 (en) 2017-07-20
HRP20160056T1 (hr) 2016-02-12
AU2012229316A1 (en) 2013-09-19
AU2012229316B2 (en) 2017-05-11
JP2014510078A (ja) 2014-04-24
ES2562332T3 (es) 2016-03-03
WO2012125475A1 (en) 2012-09-20
PH12013501820A1 (en) 2013-11-25
AR085651A1 (es) 2013-10-16
TWI542349B (zh) 2016-07-21
US20170165266A1 (en) 2017-06-15
SG192947A1 (en) 2013-09-30
US20140148473A1 (en) 2014-05-29
HUE027481T2 (en) 2016-09-28
WO2012125459A1 (en) 2012-09-20
AU2012229300B2 (en) 2017-04-20
CN103561744A (zh) 2014-02-05
AU2012229300A1 (en) 2013-09-12
JP2014508780A (ja) 2014-04-10
IL228230A (en) 2017-03-30
EA201391319A1 (ru) 2014-03-31
US20120230983A1 (en) 2012-09-13
SI2683384T1 (sl) 2016-05-31
CY1117430T1 (el) 2017-04-26
BR112013023280A2 (pt) 2017-09-19
SMT201600034B (it) 2016-04-29
MX2013010217A (es) 2013-10-25
HK1191858A1 (zh) 2014-08-08
PL2683384T3 (pl) 2016-06-30
CN107375293A (zh) 2017-11-24
EP3025715A1 (en) 2016-06-01
TW201242601A (en) 2012-11-01
US20180055844A1 (en) 2018-03-01
PH12013501837A1 (en) 2013-11-18
NZ614347A (en) 2015-09-25
EP2683384B1 (en) 2015-12-09
JP6118273B2 (ja) 2017-04-19
JP2018168159A (ja) 2018-11-01
RU2013145556A (ru) 2015-04-20

Similar Documents

Publication Publication Date Title
NI201300081A (es) Uso de 3 - ( 5 - amino - 2 - metil - 4 - oxoquinazolin - 3(4h) - il) piperidin - 2 - 6 -diona en el tratamiento de enfermedades relacionadas con el sistema inmunitario e inflamatorias.
MX2015001686A (es) Tratamiento de enfermedades inmuno - relacionadas e inflamatorias.
CY1119960T1 (el) Μεθοδοι για την αυξηση της αποτελεσματικοτητας της folr1 θεραπειας του καρκινου
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
AR089993A1 (es) Macrociclos peptidomimeticos
GT201300291A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias.
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
GT201400196A (es) Compuestos de heterociclilo
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
CO6721010A2 (es) Antagonistas de mdm2 de espiro-oxindol
MX2015003140A (es) Formulaciones de enzalutamida.
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
DOP2015000170A (es) Compuestos químicos
ECSP14013215A (es) Compuestos novedosos
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
EA201590562A1 (ru) Бензамиды
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
UY33874A (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas